Quick Read – JNJ has beaten earnings four consecutive quarters, with Q1 revenue jumping 10% to $24 billion and full-year guidance raised above $100 billion. – JNJ’s nearly $9 billion MedTech segment growing at 8% gives it diversification that ABBV and PFE simply cannot match. -…
lymarket traders price a 92% chance JNJ beats Q2 on July 15, and a planned orthopaedics spinoff adds further multiple expansion upside. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today
Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the earnings power, the dividend and the pipeline still justify stepping in before the earnings report.
Johnson & Johnson walked into 2026 with clear acceleration. Q1 revenue hit $24.06 billion, up 9.9% year over year, and adjusted EPS of $2.70 marked the fourth consecutive beat. Innovative Medicine grew 11.2% even with STELARA down 59.7%, because TREMFYA jumped 68.3%, DARZALEX rose 22.5% and CARVYKTI surged 62.1%.